Occupational Disruption and Role Strain During Perimenopause
Occupational Disruption and Role Strain During Perimenopause: A Mixed-Methods Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Perimenopause is associated with fatigue, sleep disturbance, vasomotor symptoms, mood changes, and cognitive difficulties. While the literature addresses symptom management, limited research examines the functional impact of perimenopause on daily occupations, work participation, and role performance. Occupational therapy (OT) emphasizes participation in meaningful activities; however, there is minimal research exploring occupational disruption during midlife hormonal transition. This study aims to add to the OT literature. The study aims to explore the question: How do perimenopausal symptoms impact occupational performance, role participation, and occupational balance in midlife women?
- Is perimenopausal symptom severity associated with decreased occupational balance?
- Is symptom severity associated with reduced role participation?
- How do women describe the impact of perimenopause on daily occupations? The proposed study will examine how perimenopausal symptoms influence: Work performance, Home responsibilities, cognitive functioning, sleep and fatigue, and occupational balance. The goal is to better understand how healthcare professionals, including OTs, can support women during this transition.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Christine Mulligan, OTD
- Phone Number: 5182105086
- Email: mullic@sage.edu
Study Locations
-
-
New York
-
Troy, New York, United States, 12180
- Russell Sage College
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women aged 40-55
- Self-reported perimenopausal symptoms
- Currently employed (paid or unpaid) or managing household roles
- English-speaking
Exclusion Criteria:
- Surgical menopause
- Current pregnancy
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Women
Women aged 40-55 with self-reported perimenopausal symptoms, who are surrently employed (paid or unpaid) or managing household roles and are English-speaking.
|
Participants who consent to participate will complete confidential surveys and one voluntary interview.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Occupational Balance Questionnaire (OBQ-11)
Time Frame: Baseline
|
An 11-item, self-report instrument developed to assess perceived occupational balance.
|
Baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Menopause-Specific Quality of Life Questionnaire (MENQOL)
Time Frame: Baseline
|
A validated self-report tool designed to assess the impact of menopausal symptoms on health-related quality of life.
It consists of 29 items across four domains
|
Baseline
|
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue
Time Frame: Baseline
|
Measures fatigue and its effects on daily functioning, including frequency, intensity, duration, and impact on physical, cognitive, and social activities.
|
Baseline
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Semi-structured interview
Time Frame: Baseline
|
Participants who voluntarily agree to be contacted with high symptom severity will consent to a confidential semi-structured interview.
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Christine Mulligan, Russell Sage College
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- RussellSage2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Perimenopause
-
NCT07599930RecruitingQuality of Life | Sleep | Mood | Perimenopause | Gut -Microbiota | Perimenopause-Related Depression
-
NCT07242430RecruitingPerimenopause | Perimenopause, Climacteric Syndrome | Perimenopausal Women
-
NCT07235878RecruitingPerimenopause | Perimenopause, Climacteric Syndrome | Perimenopausal Women
-
NCT07427459Recruiting
-
NCT07619352Not yet recruiting
-
NCT07597915Not yet recruitingMenopause | Perimenopause
-
NCT07590999RecruitingPerimenopause | Perimenopause-Related Depression | Perimenopausal Women | Emotional Processing and Cognitive Function in Perimenopausal Women Experiencing Cognitive Perturbations
-
NCT06018740CompletedMenopause | Perimenopause
Clinical Trials on Confidential Surveys
-
NCT02464644CompletedHereditary Hemorrhagic Telangiectasia (HHT)
-
NCT00589953TerminatedBrain Injury | Intraventricular Hemorrhage | Randomized Clinical Trial | Infant, Premature | Periventricular Leukomalacia | Neurodevelopmental Outcomes | Erythropoietin
-
NCT01458509Completed
-
NCT03552731RecruitingOncology Problem
-
NCT05877404Terminated
-
NCT02769546Terminated
-
NCT01534923CompletedColorectal Cancer Screening